Short-acting P2Y12 blockade to reduce platelet dysfunction and coagulopathy during experimental extracorporeal circulation and hypothermia

British Journal of Anaesthesia

Volumn 108, Issue 6, 2012, Pages 912-921

  Krajewski, S ^a   Kurz, J ^a   Neumann, B ^a   Greiner, T O ^a   Stolz, A ^a   Balkau, B ^b,c,d   Peter, K ^b   Unertl, K ^a   Wendel, H P ^a   Straub, A ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^c CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

cardiopulmonary bypass; extracorporeal circulation; hypothermia; platelets

Indexed keywords

2 METHYLTHIOADENOSINE 5' MONOPHOSPHATE; ADENOSINE DIPHOSPHATE; ADENOSINE PHOSPHATE; CANGRELOR; FIBRINOGEN; FIBRINOGEN RECEPTOR; GLYCOPROTEIN IB ALPHA; PLACEBO; PURINERGIC P2Y12 RECEPTOR; SHORT ACTING DRUG; THROMBIN ANTITHROMBIN COMPLEX; UNCLASSIFIED DRUG; ANTITHROMBIN III; ANTITHROMBIN III PROTEASE COMPLEX; ANTITHROMBIN III-PROTEASE COMPLEX; DRUG DERIVATIVE; PEPTIDE HYDROLASE; PURINERGIC P2Y RECEPTOR ANTAGONIST; THROMBIN RECEPTOR;

ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BODY TEMPERATURE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG ACTIVITY; EXPERIMENTAL STUDY; EXTRACORPOREAL CIRCULATION; GRANULOCYTE; HUMAN; HUMAN CELL; INDUCED HYPOTHERMIA; MALE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; SWINE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE DYSFUNCTION; THROMBOCYTE FUNCTION; ANIMAL; BLOOD; CARDIOPULMONARY BYPASS; CELL GRANULE; DRUG EFFECT; METABOLISM; PHYSIOLOGY; THROMBOCYTE;

ADENOSINE DIPHOSPHATE; ADENOSINE MONOPHOSPHATE; ANIMALS; ANTITHROMBIN III; BLOOD COAGULATION DISORDERS; BLOOD PLATELETS; CARDIOPULMONARY BYPASS; CYTOPLASMIC GRANULES; EXTRACORPOREAL CIRCULATION; HUMANS; HYPOTHERMIA, INDUCED; PEPTIDE HYDROLASES; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PURINERGIC P2Y RECEPTOR ANTAGONISTS; SWINE;

EID: 84861434519     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aer518     Document Type: Article

References (40)

1. Rajagopalan S, Mascha E, Na J, Sessler DI. The effects of mild perioperative hypothermia on blood loss and transfusion requirement. Anesthesiology 2008; 108: 71-7
2. Weerasinghe A, Taylor KM. The platelet in cardiopulmonary bypass. Ann Thorac Surg 1998; 66: 2145-52
3. Paparella D, Brister SJ, Buchanan MR. Coagulation disorders of cardiopulmonary bypass: a review. Intensive Care Med 2004; 30: 1873-81
4. Xavier RG, White AE, Fox SC, Wilcox RG, Heptinstall S. Enhanced platelet aggregation and activation under conditions of hypothermia. Thromb Haemost 2007; 98: 1266-75
5. Augoustides JG. Fatal intraoperative thrombosis in contemporary adult thoracic aortic surgery requiring deep hypothermic circulatory arrest: observations from the literature, 1993-2006. J Thorac Cardiovasc Surg 2007; 134: 1069-70
6. Hiramatsu Y, Gikakis N, Anderson HL 3rd, et al. Tirofiban provides 'platelet anesthesia' during cardiopulmonary bypass in baboons. J Thorac Cardiovasc Surg 1997; 113: 182-93
7. Straub A, Schiebold D, Wendel HP, et al. Platelet anaesthesia during extracorporeal circulation: differential effects of GP IIb/ IIIa blockers on platelet activation marker P-selectin expression at hypothermia. Thromb Res 2008; 122: 383-9
8. Harder S, Klinkhardt U, Alvarez JM. Avoidance of bleeding during surgery in patients receiving anticoagulant and/or antiplatelettherapy: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet 2004; 43: 963-81
9. Brown CH 3rd, Leverett LB, Lewis CW, Alfrey CP Jr, Hellums JD. Morphological, biochemical, and functional changes in human platelets subjected to shear stress. J Lab Clin Med 1975; 86: 462-71
10. Reimers RC, Sutera SP, Joist JH. Potentiation by red blood cells of shear-induced platelet aggregation: relative importance of chemical and physical mechanisms. Blood 1984; 64: 1200-6
11. Hall MW, Goodman PD, Solen KA, Mohammad SF. Formation of occlusive platelet aggregates in whole blood caused by low concentrations of ADP. ASAIO J 2000; 46: 693-5
12. Offermanns S. Activation of platelet function through G proteincoupled receptors. Circ Res 2006; 99: 1293-304
13. Straub A, Krajewski S, Hohmann JD, et al. Evidence of platelet activation at medically used hypothermia and mechanistic data indicating ADP as a key mediator and therapeutic target. Arterioscler Thromb Vasc Biol 2011; 31: 1607-16
14. Straub A, Wendel HP, Dietz K, et al. Selective inhibition of the platelet phosphoinositide 3-kinase p110beta as promising new strategy for platelet protection during extracorporeal circulation. Thromb Haemost 2008; 99: 609-15
15. Straub A, Breuer M, Wendel HP, et al. Critical temperature ranges of hypothermia-induced platelet activation: possible implications for cooling patients in cardiac surgery. Thromb Haemost 2007; 97: 608-16
16. Krajewski S, Kurz J, Wendel HP, Straub A. Flow cytometry analysis of porcine platelets: optimized methods for best results. Platelets Advance Access published on October 31, 2011, PMID: 22035358
17. Peter K, Kohler B, Straub A, et al. Flow cytometric monitoring of glycoprotein IIb/IIIa blockade and platelet function in patients with acute myocardial infarction receiving reteplase, abciximab, and ticlopidine: continuous platelet inhibition by the combination of abciximab and ticlopidine. Circulation 2000; 102: 1490-6
18. Gorman MW, Marble DR, Ogimoto K, Feigl EO. Measurement of adenine nucleotides in plasma. Luminescence 2003; 18: 173-81
19. Bergmeier W, Chauhan AK, Wagner DD. Glycoprotein Ibalpha and von Willebrand factor in primary platelet adhesion and thrombus formation: lessons from mutant mice. Thromb Haemost 2008; 99: 264-70
20. Hall MW, Goodman PD, Alston SM, Solen KA. ypothermia-induced platelet aggregation in heparinized flowing human blood: identification of a high responder subpopulation. Am J Hematol 2002; 69: 45-55
21. Gawaz M. Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium. Cardiovasc Res 2004; 61: 498-511
22. Uthoff K, Zehr KJ, Geerling R, et al. Inhibition of platelet adhesion during cardiopulmonary bypass reduces postoperative bleeding. Circulation 1994; 90: II269-74
23. Schrör K, Weber AA. Comparative pharmacology of GP IIb/IIIa antagonists. J Thromb Thrombolysis 2003; 15: 71-80
24. Schneider DJ, Taatjes DJ, Sobel BE. Paradoxical inhibition of fibrinogen binding and potentiation of alpha-granule release by specific types of inhibitors of glycoprotein IIb-IIIa. Cardiovasc Res 2000; 45: 437-46
25. Bassler N, Loeffler C, Mangin P, et al. A mechanistic model for paradoxical platelet activation by ligand-mimetic alphaIIb beta3 (GPIIb/IIIa) antagonists. Arterioscler Thromb Vasc Biol 2007; 27: e9-15
26. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-15
27. Cattaneo M, Podda GM. State of the art of new P2Y12 antagonists. Intern Emerg Med 2010; 5: 385-91
28. Siller-Matula JM, Krumphuber J, Jilma B. Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases. Br J Pharmacol 2010; 159: 502-17
29. Meadows TA, Bhatt DL. Clinical aspects of platelet inhibitors and thrombus formation. Circ Res 2007; 100: 1261-75
30. Fugate SE, Cudd LA. Cangrelor for treatment of coronary thrombosis. Ann Pharmacother 2006; 40: 925-30
31. Bhatt DL, Lincoff AM, Gibson CM, et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 2009; 361: 2330-41
32. Harrington RA, Stone GW,McNulty S, et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 2009; 361: 2318-29
33. Srinivasan S, Mir F, Huang JS, et al. The P2Y12 antagonists, 2-methylthioadenosine 5́-monophosphate triethylammonium salt and cangrelor (ARC69931MX), can inhibit human platelet aggregation through a Gi-independent increase in cAMP levels. J Biol Chem 2009; 284: 16108-17
34. Akers WS, Oh JJ, Oestreich JH, et al. Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: a direct, parenteral P2Y12 receptor antagonist. J Clin Pharmacol 2010; 50: 27-35
35. Savage B, Ruggeri ZM. Selective recognition of adhesive sites in urface-bound fibrinogen by glycoprotein IIb-IIIa on nonactivated platelets. J Biol Chem 1991; 266: 11227-33
36. Coade SB, Pearson JD. Metabolism of adenine nucleotides in human blood. Circ Res 1989; 65: 531-7
37. Storey RF, Wilcox RG, Heptinstall S. Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease. Platelets 2002; 13: 407-13
38. Storey RF, Oldroyd KG, Wilcox RG. Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. Thromb Haemost 2001; 85: 401-7
39. Greenbaum AB, Grines CL, Bittl JA, et al. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo-and activecontrolled trial. Am Heart J 2006; 151: 689.e1-10
40. Wendel HP, Philipp A, Weber N, Birnbaum DE, Ziemer G. Oxygenator thrombosis: worst case after development of an abnormal pressure gradient-incidence and pathway. Perfusion 2001; 16: 271-8 P2Y12 blockade during extracorporeal circulation BJA 921